What Changed
- ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
- A manager reports 5% or less of ICU Medical (ICUI), with sole voting power over 1.08M shares.
- ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
Price Move History
- Daily moves over 5%
- 4 252 sessions, November 17, 2025 to November 17, 2026
- Largest daily move
- +10.9% close of August 7, 2026
- 1-year change
- +31.5% closing prices, November 17, 2025 to November 17, 2026
- 1-month change
- +8.5% closing prices, October 16, 2026 to November 17, 2026
Company Description
ICU Medical, Inc. (Nasdaq: ICUI) is a medical technology company that focuses on the development, manufacture and sale of medical products used across a range of care settings. According to the company’s public disclosures, ICU Medical is described as a global leader in infusion systems, infusion consumables and high-value critical care products that are used in hospital, alternate site and home care environments. The company is headquartered in San Clemente, California.
ICU Medical’s business centers on products that support infusion therapy and critical care. In its communications to investors, the company highlights three primary product groupings: consumables, infusion systems and vital care. These categories are also used in the company’s financial reporting, where revenue is broken out by product line. Consumables, infusion systems and vital care together represent the core of ICU Medical’s operations and reflect its focus on clinically essential devices and related products.
The company’s financial reports show that it generates revenue by selling these medical products to clinical customers. ICU Medical notes that its team is focused on providing quality, innovation and value to clinical customers worldwide, and that its products are used in hospital, alternate site and home care settings. The company’s disclosures also state that it offers clinically essential medical devices that connect patients and caregivers through technology and services intended to provide meaningful clinical value.
ICU Medical reports its results by product line, which provides insight into how its operations are organized. The company discloses revenues for Consumables, Infusion Systems and Vital Care in its quarterly financial statements. These product lines include, among other things, infusion-related products and critical care offerings. The company has also disclosed that certain contract manufacturing activities and IV solutions-related revenue have been included within the Vital Care product line in specific periods.
In addition to its core product categories, ICU Medical has engaged in strategic transactions related to IV solutions. The company’s financial disclosures for 2025 describe an IV Solutions business that was included within the Vital Care product line and note that this business was disposed of on May 1, 2025. Separately, ICU Medical announced the formation of Otsuka ICU Medical LLC, a joint venture with Otsuka Pharmaceutical Factory, Inc. aimed at strengthening IV solutions manufacturing and innovation in the North American market. Under the terms of that joint venture, ICU Medical states that it will provide commercial services for the venture to support North American customers.
ICU Medical’s public statements also emphasize its role in IV solutions supply and manufacturing. In connection with the joint venture with Otsuka Pharmaceutical Factory, the company described the partnership as creating one of the largest global IV solutions manufacturing networks, with combined production of an estimated 1.4 billion annual units, and as intended to enhance supply chain resiliency and introduce new technologies to the North American IV solutions market. These disclosures highlight the importance of IV solutions and related products within the broader context of ICU Medical’s business.
The company’s financial filings and press releases provide further detail on its operations. ICU Medical reports on metrics such as total revenues, cost of goods sold, gross profit, operating expenses, and segment-level revenues for consumables, infusion systems and vital care. It also discusses items such as restructuring, strategic transaction and integration expenses, research and development spending, and the impact of contract manufacturing arrangements. While specific figures change over time, these disclosures indicate that ICU Medical’s business model is built around manufacturing and selling medical devices and products that support infusion therapy and critical care.
ICU Medical’s securities are listed on the Nasdaq Global Select Market under the symbol ICUI. The company files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K. In its forward-looking statements sections, ICU Medical identifies a range of risks related to its operations, such as competition, demand for its products, costs related to product development, supply chain considerations, regulatory matters, and macroeconomic and healthcare-specific factors. These disclosures provide additional context for understanding the environment in which the company operates.
Overall, ICU Medical can be characterized, based on its own public descriptions, as a manufacturer of clinically essential infusion and critical care products that are used across multiple care settings. Its reported product lines of consumables, infusion systems and vital care, along with its involvement in IV solutions manufacturing and joint ventures, frame the company’s role within the surgical and medical instrument manufacturing industry.
Business segments and product focus
ICU Medical’s financial reporting highlights three main product lines:
- Consumables – infusion-related consumable products, reported as a distinct product line in the company’s revenue disclosures.
- Infusion Systems – infusion systems products, which the company identifies as a separate revenue category.
- Vital Care – vital care products, including, in certain periods, IV Solutions revenue and contract manufacturing revenue as disclosed in the company’s financial statements.
These product lines are central to how ICU Medical presents its business to investors and regulators, and they align with the company’s description of itself as a global leader in infusion systems, infusion consumables and high-value critical care products.
Industry classification
Based on the provided classification, ICU Medical operates in the Surgical and Medical Instrument Manufacturing industry within the broader Manufacturing sector. Its focus on infusion therapy products, consumables and critical care devices places it within the medical device and equipment segment of this industry.
Stock Performance
ICU Medical (ICUI) closed at $176.91 on November 17, 2026. Over the past 12 months, the price has gained 31.5%.
ICUI Metrics & Rankings
Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
ICU Medical has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, conferences, earnings date. View all ICUI news →
SEC Filings
ICU Medical has filed 10 recent SEC filings, including 4 Form 4, 3 Form 144, 1 Form SCHEDULE 13G/A, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ICUI SEC filings →
Insider Radar
Insider selling at ICU Medical over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
ICU Medical generated $2.2B in revenue in FY2025, retaining a 36.8% gross margin, operating income reached $42.8M (1.9% operating margin), and net income was $732K, reflecting a 0.0% net profit margin. Diluted earnings per share stood at $0.03. The company generated $179.8M in operating cash flow. The current ratio was 2.39, measuring current assets divided by current liabilities.
Upcoming Events
Jefferies presentation
ICU Medical has 1 upcoming scheduled event. The next event, "Jefferies presentation", is scheduled for November 18, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the ICUI stock price.
Short Interest History
Short interest in ICU Medical (ICUI) currently stands at 1.7 million shares, down 2.4% from the previous reporting period, representing 6.8% of the float. Since November 2025, short interest has increased by 26.3%.
Days to Cover History
Days to cover for ICU Medical (ICUI) currently stands at 8.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 54.2%. Across the settlements charted above, it has ranged from 3.5 to 8.0 days.
ICUI Company Profile & Sector Positioning
ICU Medical (ICUI) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing ICUI often look at related companies in the same sector, including Stevanato Group S.p.A. (STVN), Envista Holdings Corporation (NVST), Merit Medical Systems Inc (MMSI), MiniMed Group, Inc. (MMED), and Pulse Biosciences, Inc (PLSE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ICUI's relative position within its industry.